Video

Dr. Paulson on the Utility of Liquid Biopsies Versus Tissue Biopsies

R. Steven Paulson, MD, discusses the utility of liquid biopsies versus tissue biopsies.

R. Steven Paulson, MD, physician, Texas Oncology, discusses the utility of liquid biopsies versus tissue biopsies.

Although tissue biopsy remains the gold standard in oncology, there may not be enough available tissue to perform a biopsy, explains Paulson. In these cases, a patient may need to undergo an invasive procedure to retrieve more tissue for testing.

Alternatively, a liquid biopsy may alleviate the need for an invasive procedure since it only requires a blood draw, says Paulson. A positive result with a liquid biopsy is relatively reliable; however, a negative test result should not be considered definitive.

Additionally, the turn-around time for a liquid biopsy is faster than a tissue biopsy. Therefore, if a liquid biopsy is positive, patients can begin targeted therapy earlier. However, the interpretation of liquid biopsies requires some standardization, concludes Paulson.

Related Videos
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.